MS Toronto 2026

Menu

CALL FOR ABSTRACTS

Regular Abstract Submission Is Now Open

The Scientific Program Committee welcomes the submission of abstracts for presentation at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting, to be held October 21-23 in Toronto, Canada.

Submit NOW

Deadline for Regular Abstract Submission: May 7, 2026 (11:59 PM ET)

Prepare your submission using this manual—download it and work through each section to ensure all required information is ready for your abstract.

Abstract Preparation

  1. Abstracts must be submitted online via the abstract submission site. Abstracts submitted by email or fax will not be accepted.
  2. Abstracts must be submitted in English. Please use American English spelling.
  3. Titles must be submitted in title case (e.g., “Safety of New MS Therapies”) and may not exceed 250 characters, including spaces.
  4. The abstract must include five required sections: Background, Objectives, Methods, Results, and Conclusions. The full abstract text may not exceed 2,550 characters (approx. 300 words), including headings and spaces, excluding disclosures.
  5. Case reports are generally discouraged. Exceptions may be considered if they provide significant insights or contribute uniquely to the field.
  6. All abbreviations (except MS) must be defined the first time they appear in the text (e.g., Multiple Sclerosis Impact Scale [MSIS]). Do not define abbreviations in the title.
  7. Use the abstract submission site functions for Greek letters, mathematical symbols, special characters, and formatting. Avoid complex mathematical formulae.
  8. Use generic drug names.
  9. Do not include tables, charts, or figures— these will be deleted.
  10. Source(s) of research funding or study support must be identified in the abstract at the time of submission in the Funding Source section of the abstract submission.
  11. A primary keyword must be selected during abstract submission (see list below).
  12. Authors must indicate their presentation preference during abstract submission: oral or poster presentation OR poster presentation only.
  13. The presenting author of an accepted abstract must register and attend MSToronto2026.
  14. You may edit your abstract until the submission deadline. After the deadline, no changes will be accepted. If you re-open a submitted abstract, you must re-submit the abstract again.
  15. Ensure your email address is correct. After submission, the submitter will receive a confirmation email with a PDF of the abstract and an abstract number for reference. If you do not receive a confirmation email, please contact abstracts.mstoronto@congrex.com.
  16. Duplicate submissions are not permitted. Authors may not submit multiple abstracts derived from the same study or dataset with only minor changes to the title, scope, or level of data completeness. The Scientific Program Committee reserves the right to reject duplicate submissions at any stage of the review process, or after presentation, if duplication is identified.

Important Dates

March 24, 2026

Regular Abstract Submission Opens

May 7, 2026​

Regular Abstract Submission Closes

May 12, 2026​

Late-Breaking Abstract Submission Opens

July 16, 2026

Late-Breaking Abstract Submission Closes

Late July 2026

Notification of Abstracts

Late August 2026

Notification of Late-Breaking Abstracts

The Scientific Program Committee welcomes the submission of abstracts for presentation at the 10th Joint ACTRIMS-ECTRIMS Meeting, to be held October 21-23 in Toronto, Canada.

Deadline for Regular Abstract Submission: May 7, 2026 (11:59 PM ET)

Late Breaking Abstract Submission

Late Breaking Abstract Submission opens Tuesday, May 12, 2026, following the close of Regular Abstract Submission. Please note that the Late Breaking Abstract submission period is not an extension of the Regular Abstract submission deadline.

Late Breaking Abstracts are generally intended for clinical trial results or other important findings that become available after the Regular Abstract submission deadline. If you have submitted your trial results as a regular submission, please do not submit a single subgroup analysis as a Late Breaking Abstract.

A limited number of Late Breaking Abstracts will be accepted for oral presentation during the Late Breaking session on Friday, October 23, 2026. All other accepted abstracts will be presented as posters.

  • The Scientific Program Committee reserves the right to determine the final allocation and presentation method.
  • A limited number of abstracts will be selected for oral presentation based on scientific merit and relevance to the scientific program. Submissions aligned with the program’s key topics are strongly encouraged.
  • An author may give only one oral presentation from submitted abstracts. If an author is associated with multiple abstracts selected for oral presentation, they will be contacted to confirm which abstract they will present and to designate co-authors to present the others. If no co-author is available, the abstract will not be scheduled for oral presentation.
  • If your abstract is accepted for a poster presentation, you will be asked to prepare both a printed poster and an electronic poster (ePoster). Presenting authors of poster presentations will present their posters during scheduled poster sessions at MSToronto2026.
  • If your abstract is accepted as an ePoster only, you will be asked to prepare an electronic poster only.
  • Detailed oral and poster presentation guidelines will be provided following abstract acceptance.

Abstract Topics are separated into four primary categories:

  • Clinical Aspects of MS
  • Pathology and Pathogenesis of MS
  • Imaging and Non-imaging Biomarkers
  • Therapy

Clinical Aspects of MS

  • Diagnosis & differential diagnosis
  • NMOSD & MOGAD
  • Autoimmune neurology
  • Symptoms (cognition, fatigue)
  • Pediatric MS
  • Progression & disease course
  • Epidemiology
  • Pregnancy & hormonal aspects
  • Clinical assessment tools
  • MS burden & comorbidities

Pathology and Pathogenesis of MS

  • Pathology
  • Genetics/Epigenetics
  • Experimental models
  • Immunology
  • Environmental factors
  • Mechanisms for neurodegeneration and repair

Imaging and Non-imaging Biomarkers

  • MRI
  • OCT
  • PET
  • Digital biomarkers
  • Fluid biomarkers
  • Other biomarkers
  • Big data & bioinformatics

Therapy

  • Immunomodulation/Immunosuppression
  • Repair & neuroprotection trials
  • Risk management & treatment de-escalation
  • Measurement of treatment response
  • Real-world evidence
  • Symptom management & rehabilitation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Interstate Postgraduate Medical Association (IPMA) and ACTRIMS. IPMA is accredited by ACCME to provide continuing education (CE) for physicians.

The rules governing eligibility of scientific meetings for CE are complicated and continually evolving, in particular, the rules related to submissions involving commercial interests (as defined by ACCME). Please note the following policies concerning abstracts for this meeting, some of which may differ from those of other scientific meetings you may have attended.

Abstracts accepted for oral platform presentation, for which CE credits will be offered, will be designated as such and will be clearly distinguished from non-CE work. For your submission to be included in a session that meets the requirements for AMA Category I credit and adheres to ACCME guidelines, it must meet each of the following criteria:

  1. In general, no author may be an employee of a commercial interest. Exceptions will require prior approval by our joint sponsors.
  2. The abstract, presentation, or slides may not be written, prepared, or produced by a commercial interest.
  3. The submission must be non-promotional in nature.
  4. The content must be appropriate in depth and scope for the intended physician audience.
  5. All presenting authors must complete and sign the disclosure form.

CE will not be offered for poster presentations or the Late-Breaking Abstracts session.
For abstracts selected for presentation within the accredited program, relevant financial relationships (if any) will be requested and disclosed to learners in meeting materials.  A disclosure report will be available prior to learners viewing MSToronto2026 educational content in the Event App and Digital Platform.

Source(s) of research funding or study support must be identified in the abstract at the time of submission in the Funding Source section of the abstract submission.

Abstracts submitted by Young Investigators may be considered for platform presentation during designated Free Communications Sessions. Selected presenters will be invited to give an oral presentation followed by a discussion.

If you wish to be considered for this session, please click the appropriate checkbox during the online abstract submission process.

Young Investigators are defined as individuals aged 35 or younger (born on or after January 1, 1991). Eligibility may also be extended to individuals whose study time has been interrupted due to maternity leave, caregiving responsibilities, or other justified time away from work or study.

You must upload proof of eligibility in the form of either a copy of your passport showing a clearly readable date of birth, or a maternity leave certificate or other documentation confirming a justified cause. Applications submitted without the required documentation, or received after the submission deadline, will not be considered.

Abstracts from commercial entities will be considered only for non-CE sessions or poster presentations and must include independent investigators (e.g., academics, clinicians, or scientists) as authors. Only abstracts presented by an independent investigator will be accepted.

ACTRIMS follows a modified position of the Committee on Publication Ethics regarding authorship and AI tools. Authors who use AI tools in the writing of an abstract, production of images or graphical elements of a presentation, or collection and analysis of data, must be transparent in disclosing in the Materials and Methods (or similar section) of the abstract and presentation how the AI tool was used and which tool was used. Authors do not have to disclose tools used for checking spelling or grammar. Authors are fully responsible for the content of their manuscript, even those parts produced by an AI tool, and are thus liable for any breach of publication ethics.

Each abstract will be evaluated by at least three external experts. Reviewers will receive the abstract along with author name(s) and affiliation(s) and must disclose any conflicts of interest. After external review is complete, final acceptance decisions will be made by the  the Scientific Program Committee.

Notification of acceptance or rejection of submitted Regular Abstracts will be sent to the presenting author via email in late July 2026. 

Notification of acceptance or rejection of submitted Late Breaking Abstracts will be sent to the presenting author via email in late August 2026.

Full instructions concerning preparation and presentation will be included with notifications. 

All accepted abstracts (incl. Late Breaking Abstracts) will be published in the online supplement of the Multiple Sclerosis Journal as well as on the MSToronto2026 website, event app, and digital platform.

    • Full text of Regular Abstracts will be published Wednesday, October 7, 2026
    • Full text of Late Breaking Abstracts will be published on Wednesday, October 21, 2026
  • Authors retain full copyright of their posters and presentations.
  • Trademarks (™) and registered marks (®) may be included in posters and oral presentations. Authors are responsible for ensuring proper and lawful use, including correct symbol designation and any required attribution to the rights holder.
  • ACTRIMS holds copyright for all on-demand videos and materials published on the MSToronto2026 website. Reproduction, distribution, or sharing of this content is strictly prohibited.

An accepted abstract should be withdrawn only under extraordinary circumstances. If you are unable to find a replacement presenter and must withdraw your presentation, please notify abstracts.mstoronto@congrex.com by Wednesday, October 7, 2026.

MSToronto2026 Is Now Open

Abstract submission, registration, and housing are officially live.

Submit
Register
Book
Submit
Register
Book